# US 2023/0054178 A1 · Trem compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054178 A1
- Document ID: US20230054178A1
- Status: Published application
- Kind: A1
- Application number: 17/519,120
- Filed: 2021-11-04
- Published: 2023-02-23
- Earliest claimed: 2020-04-14
- Assignees: Flagship Pioneering Innovations VI, LLC
- Applicants: Flagship Pioneering Innovations VI, LLC
- Inventors: Theonie Anastassiadis; David Charles Donnell Butler; Neil Kubica; Qingyi Li
- Web page: https://patentgrep.com/patent/US20230054178A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/712: Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/67: General methods for enhancing the expression
- C12N 2310/313: Phosphorodithioates
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/3341: 5-Methylcytosine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates generally to tRNA-based effector molecules having a non-naturally occurring modification and methods relating thereto.

## Claims

### Claim 1

A method of delivering a tRNA-based effector molecule (TREM) to a cell or a subject, wherein the TREM comprises a non-naturally occurring modification at a nucleotide position corresponding to a selected nucleotide position of a reference sequence, wherein the reference sequence is SEQ ID NO: 622, and the selected nucleotide position is selected from nucleotide positions 2, 3, and 73 of SEQ ID NO: 622.

### Claim 2 (depends on 1)

The method of claim 1, wherein the TREM comprises an RNA sequence encoded by a DNA sequence at least 95% identical to SEQ ID NO: 43.

### Claim 3 (depends on 1)

The method of claim 1, wherein the TREM comprises an RNA sequence encoded by a DNA sequence at least 95% identical to SEQ ID NO: 200.

### Claim 4 (depends on 1)

The method of claim 1, wherein the TREM comprises an RNA sequence encoded by a DNA sequence at least 95% identical to SEQ ID NO: 90.

### Claim 5 (depends on 1)

The method of claim 1, wherein the selected nucleotide position of the reference sequence is nucleotide position 2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the selected nucleotide position of the reference sequence is nucleotide position 3.

### Claim 7 (depends on 1)

The method of claim 1, wherein the selected nucleotide position of the reference sequence is nucleotide position 73.

### Claim 8 (depends on 1)

The method of claim 1, wherein the non-naturally occurring modification comprises an internucleotide modification or a 2′-modification on a nucleotide sugar moiety.

### Claim 9 (depends on 8)

The method of claim 8, wherein the non-naturally occurring modification is selected from 2′-OMe, 2′-F, 2′-deoxy, 2′-MOE, and a phosphorothioate internucleotide modification.

### Claim 10 (depends on 1)

The method of claim 1, wherein the TREM further comprises a non-naturally occurring modification at a nucleotide position corresponding to nucleotide positions 16 or 52 of SEQ ID NO: 622.

### Claim 11 (depends on 1)

The method of claim 1, wherein TREM further comprises a non-naturally occurring modification at a selected nucleotide position within the ACH domain.

### Claim 12 (depends on 1)

The method of claim 1, wherein TREM does not comprise a non-naturally occurring modification a selected nucleotide position within the ACH domain.

### Claim 13 (depends on 1)

The method of claim 1, wherein the TREM is formulated as a lipid nanoparticle.

### Claim 14 (depends on 1)

The method of claim 1, wherein the TREM is delivered to a subject having a premature termination codon (PTC) disorder.

### Claim 15 (depends on 1)

The method of claim 1, wherein the correspondence between a selected nucleotide position in the TREM and a nucleotide position in the reference sequence SEQ ID NO: 622 is determined as follows:
(a) aligning the sequence of SEQ ID NO: 622 and the sequence of the TREM based on a global pairwise alignment calculated with the Needleman-Wunsch algorithm to produce a plurality of alignments;
(b) selecting the alignment from (a) with the highest overall alignment score within the plurality;
(c) using the alignment selected in (b) to determine the percent similarity between the TREM sequence and the reference sequence SEQ ID NO: 622; and,
wherein, if the nucleotide position in the sequence of SEQ ID NO: 622 is paired with a selected nucleotide position in the TREM sequence, the positions are corresponding.

### Claim 16 (depends on 1)

The method of claim 1, wherein the correspondence between a selected nucleotide position in the TREM and a nucleotide position in the reference sequence SEQ ID NO: 622 is determined as follows:
(a) aligning the sequence of the TREM with a plurality of isodecoder consensus sequences, wherein the alignment is performed as follows;
(i) aligning the TREM sequence and an isodecoder consensus sequence from the plurality based on a global pairwise alignment calculated with the Needleman-Wunsch algorithm;
(ii) selecting the alignment from (i) with the highest overall alignment score within the plurality;
(iii) using the alignment selected in (ii) to determine the percent similarity between the TREM sequence and the consensus sequence within the plurality by counting the number of matched positions in the alignment;
(iv) repeating steps (i)-(iii) for each of the remaining isodecoder consensus sequences in the plurality, wherein the alignment resulting in the greatest percent similarity is selected;
wherein if this alignment has a percent similarity equal to or greater than 60%, it is considered a valid alignment and used to relate positions in the TREM sequence to those in the consensus sequence,
(b) comparing whether the value for a nucleotide position number determined for the TREM sequence in step (iv) is the same as the value for the position number determined for the reference sequence SEQ ID NO: 622, the positions are defined as corresponding.

### Claim 17

A method of delivering a tRNA-based effector molecule (TREM) to a cell or a subject, wherein the TREM has a sequence with 95% sequence identity to SEQ ID NO: 622 and comprises a non-naturally occurring modification at a nucleotide position selected from nucleotide positions 2, 3, 16, 52, and 73 of SEQ ID NO: 622.

### Claim 18 (depends on 17)

The method of claim 17, wherein the non-naturally occurring modification is selected from 2′-OMe, 2′-F, 2′-deoxy, 2′-MOE, and a phosphorothioate internucleotide modification.
